The Market Reports

Synopsis
The global market for Biosimilar Insulin was estimated to be worth US$ 3329 million in 2024 and is forecast to a readjusted size of US$ 8329 million by 2031 with a CAGR of 14.2% during the forecast period 2025-2031.
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
The biosimilar insulin market is primarily driven by the growing demand for affordable diabetes management solutions. As the prevalence of diabetes continues to rise globally, especially in emerging markets, there is an increasing need for cost-effective alternatives to branded insulin products. Biosimilar insulins offer similar therapeutic effects as their originator counterparts but at a lower price, making them more accessible to patients and healthcare systems. Additionally, the expiration of patents for several major insulin products has opened the door for the introduction of biosimilars, further driving market growth. The increasing adoption of biosimilars in both developed and developing countries is expected to continue, as they help reduce the financial burden on healthcare systems while maintaining high standards of care.
However, the biosimilar insulin market faces challenges related to regulatory approval processes and market acceptance. Biosimilars, although similar in composition, are not identical to their reference biologics, leading to concerns over safety and efficacy, particularly in long-term use. Regulatory bodies require rigorous testing and clinical trials to ensure that biosimilar insulins meet the necessary standards, which can delay their entry into the market. Furthermore, the market is also challenged by resistance from healthcare professionals and patients who may be hesitant to switch from branded to biosimilar insulin due to unfamiliarity or perceived risks. Additionally, competition from other diabetes therapies, such as oral medications and innovative insulin delivery devices, could also impact the growth of the biosimilar insulin market.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Insulin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Biosimilar Insulin by region & country, by Type, and by Distribution Channel.
The Biosimilar Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Insulin.
Market Segmentation
By Company
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Segment by Type
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Segment by Distribution Channel
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Biosimilar Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Biosimilar Insulin in country level. It provides sigmate data by Type, and by Distribution Channel for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index